Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris

Main Article Content

L Eichenfield
Rady Children?s Hospital, University of California San Diego, San Diego, CA

L Stein Gold
Henry Ford Health System, Detroit, MI

N Silverberg
Mount Sinai Health System, New York, NY

T Raoof
T. Joseph Raoof MD Inc./Encino Research Center, Encino, CA

D Hooper
Delricht Research, New Orleans, LA

A Moore
Arlington Research Center, Arlington, TX/Baylor University Medical Center, Dallas, TX

M Zaiac
Department of Dermatology, Herbert Wertheim College of Medicine, Florida International University and Greater Miami Skin and Laser Center, Miami Beach, FL

T Sullivan
Sullivan Dermatology, North Miami Beach, FL

L Kircik
9Ichan School of Medicine at Mount Sinai, New York, NY

E Lain
Austin Institute for Clinical Research, Austin, TX

S Dhawan
Center for Dermatology Clinical Research, Inc., Freemont, CA

T Jones
J&S Studies, Inc., College Station, TX

J Weiss
Gwinnett Dermatology, Freemont, CA;

Z Draelos
Dermatology Consulting Services, Snellville, GA

H Ellman
Formerly Foamix Pharmaceuticals, Inc. (Ret.), Bridgewater, NJ

T deVries
TM deVries Consulting, LLC, Bridgewater, NJ

J Jankicevic
Clinical Development & Medical Affairs Consulting, San Jose, CA

I Stuart
Foamix Pharmaceuticals, Inc., Bridgewater, NJ

Keywords

acne, minocycline

Abstract

Abstract not available.

References

1. Thiboutot DM, Dreno B, Abanmi, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2S1):S1-S23.e1.

2. Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;CD002086.

3. Yentzer BA, Hick J, Reese EL, et al. Acne Vulgaris in the United States: a descriptive epidemiology. Cutis. 2010;86:94-99.

4. Zaenglein AL, PathyAL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33.

5. Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019;80:168-177.

6. Jones TM, Ellman H, deVries T. Pharmacokinetic comparison of once-daily topical minocycline foam 4% vs oral minocycline for moderate-to-severe acne. J Drugs Dermatol. 2017;16:1022-1028.

Article Sidebar

Poster PDF
Published
Nov 9, 2019
DOI https://doi.org/10.25251/skin.3.supp.2

Article Details

How to Cite
Eichenfield, L., Gold, L. S., Silverberg, N., Raoof, T., Hooper, D., Moore, A., Zaiac, M., Sullivan, T., Kircik, L., Lain, E., Dhawan, S., Jones, T., Weiss, J., Draelos, Z., Ellman, H., deVries, T., Jankicevic, J., & Stuart, I. (2019). Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris. SKIN The Journal of Cutaneous Medicine, 3, S2. https://doi.org/10.25251/skin.3.supp.2
Issue
Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)